Transformative Innovation in the Field of Chronic Wound Care

Aurealis Therapeutics offers a breakthrough solution
for a massive unmet need and market.

Chronic wounds, such as diabetic foot ulcers, venous leg ulcers and pressure ulcers, contribute major costs to healthcare systems and societies. Just in the United States, 8.2 million patients are impacted annually by non-healing wounds and related complications. The global market for chronic wound care is estimated at $10 billion, with a 5% annual growth rate, revealing a need for better treatment options than the ones currently available. The market is dominated by basic wound care products, advanced dressings, cellular and tissue based products, and medical devices. No approved drugs are marketed in USA and Europe, posing an untapped market for the first movers.   


Aurealis Therapeutics is an innovative biotechnology company seeking to differentiate by offering a prescription drug with superior efficacy to these unmet medical indications and market. Our disruptive wound healing technology offers multiple benefits over conventional treatments and therapies, including:

  • Combination therapy: four therapeutic components in one product
  • Safe: extensively studied food-grade lactic acid bacteria
  • Topical: therapeutic agents produced at the wound site
  • Scalable: low-cost and scaled GMP production


Genetically modified lactic acid bacterial therapies are a game-changer for regenerative medicine that solves the problems of efficacy, safety, scale-up, cost and delivery of the therapeutic agents. Our first therapeutic product, AUP-16, has been extensively studied in pre-clinical settings, demonstrating its safety and effectiveness in wound healing.

Efficient

Multi-therapeutic
Continous, on-site action
1

Low Cost

Scalable
Low manufacturing cost
2

Safe

Non-pathogenic
Local administration
3

Easy

Logistically stable
No special handling required
4

Burden of Chronic Wounds

4 min & 6.5 min

Annual incidence
EU & US

30%

2-year
mortality rate

1 amputation

Every 30
seconds

25-50%

Hospital beds
occupied

12%

Rising prevalence
per year

Clinical trial for DFU: Our first-in-human clinical trial of AUP-16 commenced in early 2020 in Germany and Poland as a phase 1/2A trial for diabetic foot ulcer (DFU) patients.  After a temporary interruption due to COVID-19, repeated dosing studies resumed in September 2020. We have seen encouraging initial results and look forward to reporting more findings as soon as possible.

Product Discovery GLP S&T CMC IND/CTA Phase 1 Phase 2 Phase 3 NDA

AUP-16 DFU
*
AUP-16
VLU, PU
AUP-16
Other inflammatory
disease applications

We are looking to expand the list of indications for our products to include other chronic wounds, such as Venous Leg Ulcers, Pressure Ulcers and others.

Learn more

Reach out to us if you are interested in becoming an Investor or Strategic Partner

Contact us